CN115427073A - 去优化SARS-CoV-2及其方法和用途 - Google Patents

去优化SARS-CoV-2及其方法和用途 Download PDF

Info

Publication number
CN115427073A
CN115427073A CN202180024216.XA CN202180024216A CN115427073A CN 115427073 A CN115427073 A CN 115427073A CN 202180024216 A CN202180024216 A CN 202180024216A CN 115427073 A CN115427073 A CN 115427073A
Authority
CN
China
Prior art keywords
cov
sars
coronavirus
polynucleotide
various embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180024216.XA
Other languages
English (en)
Chinese (zh)
Inventor
斯特芬·穆勒
约翰·罗伯特·科尔曼
王颖
杨晨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serum Institute of India Pvt Ltd
Kodak Jinnix Co ltd
Original Assignee
Serum Institute of India Pvt Ltd
Kodak Jinnix Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute of India Pvt Ltd, Kodak Jinnix Co ltd filed Critical Serum Institute of India Pvt Ltd
Publication of CN115427073A publication Critical patent/CN115427073A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
CN202180024216.XA 2020-01-28 2021-01-27 去优化SARS-CoV-2及其方法和用途 Pending CN115427073A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062966750P 2020-01-28 2020-01-28
US62/966,750 2020-01-28
US202063048942P 2020-07-07 2020-07-07
US63/048,942 2020-07-07
US202063079337P 2020-09-16 2020-09-16
US63/079,337 2020-09-16
US202063079853P 2020-09-17 2020-09-17
US63/079,853 2020-09-17
PCT/US2021/015246 WO2021154828A1 (en) 2020-01-28 2021-01-27 DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF

Publications (1)

Publication Number Publication Date
CN115427073A true CN115427073A (zh) 2022-12-02

Family

ID=77078567

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180024216.XA Pending CN115427073A (zh) 2020-01-28 2021-01-27 去优化SARS-CoV-2及其方法和用途

Country Status (17)

Country Link
US (1) US20230117167A1 (https=)
EP (1) EP4096712A4 (https=)
JP (1) JP2023519640A (https=)
KR (1) KR20220132588A (https=)
CN (1) CN115427073A (https=)
AU (1) AU2021213121A1 (https=)
BR (1) BR112022014700A2 (https=)
CA (1) CA3168100A1 (https=)
CL (1) CL2022002030A1 (https=)
CO (1) CO2022010743A2 (https=)
IL (1) IL295112A (https=)
MX (1) MX2022009099A (https=)
PE (1) PE20230166A1 (https=)
PH (1) PH12022551788A1 (https=)
SA (1) SA522433428B1 (https=)
TW (1) TW202144570A (https=)
WO (1) WO2021154828A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12029786B2 (en) * 2020-02-07 2024-07-09 RNAimmune, Inc. Composition and method of mRNA vaccines against novel coronavirus infection
US20230057087A1 (en) * 2020-03-06 2023-02-23 Genomictree, Inc. Composition for diagnosing sars-cov-2, kit, and method for diagnosing sars-cov-2 by using same
US12558415B2 (en) * 2020-04-14 2026-02-24 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
EP4181956A4 (en) * 2020-07-16 2024-08-07 Griffith University VACCINE AGAINST A LIVE ATTENUATED VIRUS
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
JP2024530672A (ja) 2021-08-11 2024-08-23 アールエヌエーイミューン、インコーポレイテッド 新規なコロナウイルス感染症に対するｍＲＮＡワクチンの組成物および方法
WO2023037387A2 (en) 2021-09-08 2023-03-16 Serum Institute Of India Private Limited Freeze-dried viral combination vaccine compositions and process for preparation thereof
EP4466014A1 (en) * 2022-01-20 2024-11-27 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
WO2023186946A1 (en) * 2022-03-28 2023-10-05 Universität Bern One-to-stop attenuated sars-cov-2 virus
EP4331602A1 (en) * 2022-09-05 2024-03-06 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
KR20250060275A (ko) 2022-09-05 2025-05-07 프라이 유니베르시탯 베를린 살아있는 약독화된 SARS-CoV-2 및 이의 제조 백신
CN120676963A (zh) * 2022-10-12 2025-09-19 伯尔尼大学 使用一至终止减毒的SARS-CoV-2病毒的治疗
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
US12280104B2 (en) 2022-11-01 2025-04-22 RNAimmune, Inc. Composition and methods for MRNA vaccines against novel omicron coronavirus infections
WO2025081050A1 (en) * 2023-10-13 2025-04-17 Duke University Coronavirus stem helix and fusion peptide nanoparticle vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
CA2587084C (en) * 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
KR101621100B1 (ko) * 2007-03-30 2016-05-13 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 백신에 유용한 약독화 바이러스
US20120269849A1 (en) * 2009-10-09 2012-10-25 Eckard Wimmer Attenuated influenza viruses and vaccines
WO2017100756A1 (en) * 2015-12-11 2017-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant respiratory syncytial virus strains comprising ns1 and ns2 gene shifts
KR20260047644A (ko) * 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도
JP2021500880A (ja) * 2017-10-16 2021-01-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ２つの発現カセットを有するサルアデノウイルスベクター

Also Published As

Publication number Publication date
AU2021213121A1 (en) 2022-08-18
PE20230166A1 (es) 2023-02-01
CA3168100A1 (en) 2021-08-05
MX2022009099A (es) 2022-10-20
CO2022010743A2 (es) 2022-08-30
WO2021154828A1 (en) 2021-08-05
BR112022014700A2 (pt) 2022-10-11
TW202144570A (zh) 2021-12-01
US20230117167A1 (en) 2023-04-20
KR20220132588A (ko) 2022-09-30
JP2023519640A (ja) 2023-05-11
EP4096712A4 (en) 2024-05-08
SA522433428B1 (ar) 2024-10-08
CL2022002030A1 (es) 2023-03-10
EP4096712A1 (en) 2022-12-07
PH12022551788A1 (en) 2024-02-26
IL295112A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CN115427073A (zh) 去优化SARS-CoV-2及其方法和用途
Chen et al. Overview of lethal human coronaviruses
CN111560354A (zh) 重组新型冠状病毒及其制备方法和应用
KR102472939B1 (ko) 페스티바이러스
CN102459578A (zh) 基于在北美狗中循环的犬瘟热病毒的免疫原性组合物、疫苗和诊断方法
US20210401983A1 (en) Arthrogenic alphavirus vaccine
CN113748203B (zh) 重组经典猪瘟病毒
US20240299533A1 (en) Deoptimized sars-cov-2 variants and methods and uses thereof
JP6538071B2 (ja) 非天然発生のブタ生殖器呼吸器症候群ウイルス（ｐｒｒｓｖ）及び使用する方法
EP2571519B1 (en) Marker vaccine for classical swine fever
CN105218668B (zh) 马耳他型布氏杆菌的EF-Tu蛋白单克隆抗体MAb及其制备方法与应用
CN1242065C (zh) 猪繁殖与呼吸综合征重组腺病毒和疫苗
CN101092631B (zh) 一种修饰的猪圆环病毒2型orf2基因及应用
CN101386830B (zh) 一种带有免疫标记的羊种布鲁氏菌的重组菌及其应用
KR20230038205A (ko) 키메라 rsv 및 코로나바이러스 단백질, 면역원성 조성물, 및 사용 방법
WO2025149032A1 (en) Respiratory syncytial virus vaccine compositions and their use
CN111518776A (zh) 一种重组狂犬病病毒疫苗株及其制备方法
CN101575587A (zh) 一种流产布鲁氏菌重组菌及其在制备疫苗中的应用
HK40060584B (zh) 重组经典猪瘟病毒
CN117618550A (zh) 流感病毒、新型冠状病毒、呼吸道合胞病毒三联疫苗及其制备方法
CN117210496A (zh) 一种新型冠状病毒的免疫原及其应用
CN115851621A (zh) 一种重组狂犬病病毒疫苗株及其制备方法
HK40060584A (en) Recombinant classical swine fever virus
BR112018074277B1 (pt) Proteína do capsídeo mutada de vírus chikungunya (chikv) isolada, purificada, sintética ou recombinante, poliproteína estrutural nascente de chikv isolada, purificada, sintética ou recombinante, chikv recombinante, alfavírus quimérico, usos dos mesmos, bem como vacina e método de preparo da mesma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination